These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36961853)

  • 21. Cost-effectiveness of public health strategies for COVID-19 epidemic control in South Africa: a microsimulation modelling study.
    Reddy KP; Shebl FM; Foote JHA; Harling G; Scott JA; Panella C; Fitzmaurice KP; Flanagan C; Hyle EP; Neilan AM; Mohareb AM; Bekker LG; Lessells RJ; Ciaranello AL; Wood R; Losina E; Freedberg KA; Kazemian P; Siedner MJ
    Lancet Glob Health; 2021 Feb; 9(2):e120-e129. PubMed ID: 33188729
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection.
    Dinnes J; Deeks JJ; Berhane S; Taylor M; Adriano A; Davenport C; Dittrich S; Emperador D; Takwoingi Y; Cunningham J; Beese S; Domen J; Dretzke J; Ferrante di Ruffano L; Harris IM; Price MJ; Taylor-Phillips S; Hooft L; Leeflang MM; McInnes MD; Spijker R; Van den Bruel A;
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013705. PubMed ID: 33760236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determinants of SARS-CoV-2 nasopharyngeal testing in a rural community sample susceptible of first infection: the CHRIS COVID-19 study.
    Giardiello D; Melotti R; Barbieri G; Gögele M; Weichenberger CX; Foco L; Bottigliengo D; Barin L; Lundin R; Pramstaller PP; Pattaro C
    Pathog Glob Health; 2023 Dec; 117(8):744-753. PubMed ID: 36992656
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Universal COVID-19 screening of 4040 health care workers in a resource-limited setting: an Egyptian pilot model in a university with 12 public hospitals and medical centers.
    Mostafa A; Kandil S; El-Sayed MH; Girgis S; Hafez H; Yosef M; Saber S; Ezzelarab H; Ramadan M; Afifi I; Hassan F; Elsayed S; Reda A; Fattuh D; Mahmoud A; Mansour A; Sabry M; Habeb P; Ebeid FS; Saleh A; Mansour O; Omar A; El-Meteini M
    Int J Epidemiol; 2021 Mar; 50(1):50-61. PubMed ID: 33094320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determining the optimal strategy for reopening schools, the impact of test and trace interventions, and the risk of occurrence of a second COVID-19 epidemic wave in the UK: a modelling study.
    Panovska-Griffiths J; Kerr CC; Stuart RM; Mistry D; Klein DJ; Viner RM; Bonell C
    Lancet Child Adolesc Health; 2020 Nov; 4(11):817-827. PubMed ID: 32758453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Testing the identification effectiveness of an unknown outbreak of the Infectious Diseases Seeker (IDS) using and comparing the novel coronavirus disease (COVID-19) outbreak with the past SARS and MERS epidemics.
    Baldassi F; Cenciarelli O; Malizia A; Gaudio P
    J Infect Public Health; 2021 Jan; 14(1):123-130. PubMed ID: 33412372
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Physical interventions to interrupt or reduce the spread of respiratory viruses.
    Jefferson T; Del Mar CB; Dooley L; Ferroni E; Al-Ansary LA; Bawazeer GA; van Driel ML; Jones MA; Thorning S; Beller EM; Clark J; Hoffmann TC; Glasziou PP; Conly JM
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD006207. PubMed ID: 33215698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Applications of separation technology in novel coronavirus research, epidemic prevention and detection].
    Li L; Zhu C; Zhao X; Qu F
    Se Pu; 2021 Jul; 39(7):679-685. PubMed ID: 34227364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative cost-effectiveness of SARS-CoV-2 testing strategies in the USA: a modelling study.
    Du Z; Pandey A; Bai Y; Fitzpatrick MC; Chinazzi M; Pastore Y Piontti A; Lachmann M; Vespignani A; Cowling BJ; Galvani AP; Meyers LA
    Lancet Public Health; 2021 Mar; 6(3):e184-e191. PubMed ID: 33549196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SARS-CoV-2 infection and mortality during the first epidemic wave in Madurai, south India: a prospective, active surveillance study.
    Laxminarayan R; B CM; G VT; Arjun Kumar KV; Wahl B; Lewnard JA
    Lancet Infect Dis; 2021 Dec; 21(12):1665-1676. PubMed ID: 34399090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SARS-CoV-2 IgG Seroprevalence among Blood Donors as a Monitor of the COVID-19 Epidemic, Brazil.
    Chaves DG; Takahashi RHC; Campelo F; da Silva Malta MCF; de Oliveira IR; Barbosa-Stancioli EF; Ribeiro MA; Martins ML
    Emerg Infect Dis; 2022 Apr; 28(4):734-742. PubMed ID: 35180375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An SEIR Model with Time-Varying Coefficients for Analyzing the SARS-CoV-2 Epidemic.
    Girardi P; Gaetan C
    Risk Anal; 2023 Jan; 43(1):144-155. PubMed ID: 34799850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Performance of Three Tests for SARS-CoV-2 on a University Campus Estimated Jointly with Bayesian Latent Class Modeling.
    Perkins TA; Stephens M; Alvarez Barrios W; Cavany S; Rulli L; Pfrender ME
    Microbiol Spectr; 2022 Feb; 10(1):e0122021. PubMed ID: 35044220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of SARS-CoV-2 surveillance outputs produced by the UK health security agency (UKHSA) outbreak surveillance team on decision-making by local stakeholders.
    Willgert K; Hardstaff J; Shadwell S; Bhattacharya A; Blomquist P; Vivancos R; Simms I
    BMC Public Health; 2023 May; 23(1):926. PubMed ID: 37217907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impacts of reopening strategies for COVID-19 epidemic: a modeling study in Piedmont region.
    Pernice S; Castagno P; Marcotulli L; Maule MM; Richiardi L; Moirano G; Sereno M; Cordero F; Beccuti M
    BMC Infect Dis; 2020 Oct; 20(1):798. PubMed ID: 33115434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of molecular testing strategies for COVID-19 control: a mathematical modelling study.
    Grassly NC; Pons-Salort M; Parker EPK; White PJ; Ferguson NM;
    Lancet Infect Dis; 2020 Dec; 20(12):1381-1389. PubMed ID: 32822577
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Measures implemented in the school setting to contain the COVID-19 pandemic.
    Krishnaratne S; Littlecott H; Sell K; Burns J; Rabe JE; Stratil JM; Litwin T; Kreutz C; Coenen M; Geffert K; Boger AH; Movsisyan A; Kratzer S; Klinger C; Wabnitz K; Strahwald B; Verboom B; Rehfuess E; Biallas RL; Jung-Sievers C; Voss S; Pfadenhauer LM
    Cochrane Database Syst Rev; 2022 Jan; 1(1):CD015029. PubMed ID: 35037252
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simple Questionnaires to Improve Pooling Strategies for SARS-CoV-2 Laboratory Testing.
    Schneitler S; Jung P; Bub F; Alhussein F; Benthien S; Berger FK; Berkó-Göttel B; Eisenbeis J; Hahn D; Halfmann A; Last K; Linxweiler M; Lohse S; Papan C; Pfuhl T; Rissland J; Roth S; Schlotthauer U; Utzinger J; Smola S; Gärtner BC; Becker SL
    Ann Glob Health; 2020 Nov; 86(1):148. PubMed ID: 33262937
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020-21.
    Cohen C; Kleynhans J; von Gottberg A; McMorrow ML; Wolter N; Bhiman JN; Moyes J; du Plessis M; Carrim M; Buys A; Martinson NA; Kahn K; Tollman S; Lebina L; Wafawanaka F; du Toit JD; Gómez-Olivé FX; Dawood FS; Mkhencele T; Sun K; Viboud C; Tempia S;
    Lancet Infect Dis; 2022 Jun; 22(6):821-834. PubMed ID: 35298900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of mass testing during an epidemic rebound of SARS-CoV-2: a modelling study using the example of France.
    Bosetti P; Kiem CT; Yazdanpanah Y; Fontanet A; Lina B; Colizza V; Cauchemez S
    Euro Surveill; 2021 Jan; 26(1):. PubMed ID: 33413741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.